Notably, in prostate cancer, elevated FAM174B expression correlates with high KLK2 levels but predicts poorer responses to immune checkpoint inhibitors, hinting at a complex immunomodulatory function that warrants further investigation 21. Here, FAM174B is linked to prostate carcinoma.